<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.168214.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Exploration of 
                    <italic>Amomum cardamomum</italic> Seed-Derived Compounds: LC-MS Profiling, Network Pharmacology, and Computational Analyses for Innovative Multi-Targeted Breast&#x00a0;Cancer&#x00a0;Therapy</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 2 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Arisanty</surname>
                        <given-names>Dessy</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-5039-5352</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Khairani</surname>
                        <given-names>Salsabila Putri</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-5460-2312</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Cuandra</surname>
                        <given-names>Kevin Nathaniel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0009-0007-7785-7474</uri>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Rahman</surname>
                        <given-names>Aldi Tamara</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-3151-5360</uri>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Tristan</surname>
                        <given-names>Christopher Daniel</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0009-4105-8739</uri>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Yahono</surname>
                        <given-names>Angela Stephanie</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0003-0448-7311</uri>
                    <xref ref-type="aff" rid="a6">6</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Ilham</surname>
                        <given-names>Muhammad Samudra</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a7">7</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Alamsyah</surname>
                        <given-names>Ajib Zaim</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0009-1386-0935</uri>
                    <xref ref-type="aff" rid="a8">8</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Sarjono</surname>
                        <given-names>Bezalel Tioleyson</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a9">9</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Setiya</surname>
                        <given-names>Daivan Febri Juan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0000-2528-8459</uri>
                    <xref ref-type="aff" rid="a10">10</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Huang</surname>
                        <given-names>Phelia Klarissa</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Hafidza</surname>
                        <given-names>Alya Jihan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0005-0845-7894</uri>
                    <xref ref-type="aff" rid="a11">11</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Hakam</surname>
                        <given-names>Afiq Triyandi</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a12">12</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Hamka</surname>
                        <given-names>Muhammad Farid</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0009-0006-4978-8080</uri>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Rasendriya</surname>
                        <given-names>Daffa Zachary</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Hibatullah</surname>
                        <given-names>Muhammad Naufal</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a13">13</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Sumargo</surname>
                        <given-names>Kuni Zakiyyah</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a14">14</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Biochemistry, Universitas Andalas Faculty of Medicine, Padang, West Sumatra, Indonesia</aff>
                <aff id="a2">
                    <label>2</label>Biomedical Science, Universitas Andalas Faculty of Medicine, Padang, West Sumatra, Indonesia</aff>
                <aff id="a3">
                    <label>3</label>Medicine, Universitas Andalas Faculty of Medicine, Padang, West Sumatra, Indonesia</aff>
                <aff id="a4">
                    <label>4</label>Obstetrics and Gynecology, Cipto Mangunkusumo Hospital, Jakarta, Special Capital Region of Jakarta, Indonesia</aff>
                <aff id="a5">
                    <label>5</label>Medicine, Universitas Sebelas Maret Faculty of Medicine, Surakarta, Central Java, Indonesia</aff>
                <aff id="a6">
                    <label>6</label>Medicine, Universitas Gadjah Mada Faculty of Medicine Public Health and Nursing, Sleman, Special Region of Yogyakarta, Indonesia</aff>
                <aff id="a7">
                    <label>7</label>Biology, Universitas Andalas Faculty of Mathematics and Natural Sciences, Padang, West Sumatra, Indonesia</aff>
                <aff id="a8">
                    <label>8</label>Medicine, Universitas Udayana Faculty of Medicine, Denpasar, Bali, Indonesia</aff>
                <aff id="a9">
                    <label>9</label>Medicine, Universitas Sam Ratulangi Faculty of Medicine, Manado, North Sulawesi, Indonesia</aff>
                <aff id="a10">
                    <label>10</label>Medicine, Universitas Islam Indonesia Faculty of Medicine, Sleman, Special Region of Yogyakarta, Indonesia</aff>
                <aff id="a11">
                    <label>11</label>Nutritional Science, Universitas Pembangunan Nasional Veteran Jakarta Faculty of Health Science, Jakarta, Special Capital Region of Jakarta, Indonesia</aff>
                <aff id="a12">
                    <label>12</label>Medicine, Universitas Sumatera Utara Faculty of Medicine, Medan, North Sumatra, Indonesia</aff>
                <aff id="a13">
                    <label>13</label>Medicine, Universitas Jember Faculty of Medicine, Jember, East Java, Indonesia</aff>
                <aff id="a14">
                    <label>14</label>Medicine, Universitas Negeri Gorontalo Faculty of Medicine, Gorontalo City, Gorontalo, Indonesia</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:dessyarisanty@med.unand.ac.id">dessyarisanty@med.unand.ac.id</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>8</day>
                <month>12</month>
                <year>2025</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2025</year>
            </pub-date>
            <volume>14</volume>
            <elocation-id>1374</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>1</day>
                    <month>12</month>
                    <year>2025</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Arisanty D et al.</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/14-1374/pdf"/>
            <abstract>
                <sec>
                    <title>Background</title>
                    <p>Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. 
                        <italic toggle="yes">A. cardamomum</italic> has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated.</p>
                </sec>
                <sec>
                    <title>Methods</title>
                    <p>This study integrated 
                        <italic toggle="yes">in silico</italic> approaches to investigate the therapeutic potential of 
                        <italic toggle="yes">A. cardamomum</italic> seed extract against breast cancer. LC&#x2013;MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski&#x2019;s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins.</p>
                </sec>
                <sec>
                    <title>Results</title>
                    <p>LC-MS profiling identified 22 distinct compounds in 
                        <italic toggle="yes">A. cardamomum</italic> seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-&#x03b1;, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand&#x2013;protein interactions.</p>
                </sec>
                <sec>
                    <title>Conclusion</title>
                    <p>This study highlights the promising multi-target anticancer potential of 
                        <italic toggle="yes">A. cardamomum</italic> seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that 
                        <italic toggle="yes">A. cardamomum</italic> could serve as a potential source for developing new plant-based therapies against breast cancer. Further 
                        <italic toggle="yes">in vitro</italic> and 
                        <italic toggle="yes">in vivo</italic> investigations are warranted to validate their efficacy and safety.</p>
                </sec>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Amomum cardamomum</kwd>
                <kwd>breast cancer</kwd>
                <kwd>LC-MS</kwd>
                <kwd>network pharmacology</kwd>
                <kwd>molecular docking</kwd>
                <kwd>drug discovery</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec5" sec-type="intro">
            <title>1. Introduction</title>
            <p>

                <italic toggle="yes">B</italic>reast cancer is one of the most common cancers in women worldwide and a leading cause of cancer-related deaths (
                <xref ref-type="bibr" rid="ref29">Ye et al., 2023</xref>). According to the World Health Organization (WHO), over 2.3 million new cases of breast cancer were diagnosed globally in 2024 (
                <xref ref-type="bibr" rid="ref27">World Health Organization, 2024</xref>). It remains a significant public health challenge due to its high incidence and mortality rates, particularly in low- and middle-income countries with limited access to early detection and advanced treatments (
                <xref ref-type="bibr" rid="ref6">Francies et al., 2020</xref>; 
                <xref ref-type="bibr" rid="ref16">Manson &amp; Achel, 2023</xref>). Despite advancements in therapeutic strategies such as chemotherapy, targeted therapy, and immunotherapy, breast cancer treatment continues to face challenges, including drug resistance, systemic toxicity, and limited efficacy in aggressive or resistant subtypes (
                <xref ref-type="bibr" rid="ref14">Liu et al., 2024</xref>; 
                <xref ref-type="bibr" rid="ref29">Ye et al., 2023</xref>). These limitations highlight the critical need for novel therapeutic agents with improved safety and efficacy profiles.</p>
            <p>

                <italic toggle="yes">Amomum cardamomum</italic> (Java cardamom), a member of the 
                <italic toggle="yes">Zingiberaceae family,
</italic> is a medicinal plant traditionally valued for its antimicrobial, anti-inflammatory, and antioxidant properties. Our previous study demonstrated that A. cardamomum exhibits significant anticancer activity against breast cancer cell lines, including its ability to inhibit cancer cell proliferation and induce apoptosis (
                <xref ref-type="bibr" rid="ref12">Khairani et al., 2024</xref>). These findings provided strong preliminary evidence of 
                <italic toggle="yes">A. cardamomum</italic>&#x2019;s potential as a therapeutic agent for breast cancer. Building on this foundation, the present study aims to further explore the therapeutic potential of 
                <italic toggle="yes">A. cardamomum</italic> by elucidating the bioactive compounds responsible for its anticancer effects and their underlying mechanisms of action. Using Liquid Chromatography-Mass Spectrometry (LC-MS), we identified and characterized the phytochemicals present in A. cardamom. A network pharmacology approach was employed to identify key protein targets and pathways associated with these compounds to complement this. Molecular docking studies and molecular dynamics simulations assessed these compounds&#x2019; binding interactions and stability with their targets. Additionally, ADMET profiling and toxicity assessments were conducted to evaluate the drug-likeness and safety of the identified compounds
                <italic toggle="yes">.</italic>
            </p>
            <p>This study represents a critical step in advancing the understanding of 
                <italic toggle="yes">A. cardamomum</italic>&#x2019;s bioactive potential and its application in addressing the challenges of breast cancer therapy. By integrating in vitro findings, compound characterization, and computational approaches, we aim to provide insights that could contribute to developing novel, plant-based therapeutics for breast cancer treatment.</p>
        </sec>
        <sec id="sec6" sec-type="methods">
            <title>2. Methods</title>
            <p>This study employed a multi-faceted methodological framework to comprehensively evaluate the therapeutic potential of 
                <italic toggle="yes">A. cardamomum</italic> for cancer treatment. The methods included LC-MS analysis for compound identification, network pharmacology to identify key protein targets, molecular docking and dynamics to analyze ligand-target interactions, and ADMET profiling and toxicity assessments to evaluate drug-likeness and safety. Each method was selected to address specific aspects of the study objectives and to ensure a thorough investigation of 
                <italic toggle="yes">A. cardamomum</italic>&#x2019;s bioactive compounds.</p>
            <sec id="sec7">
                <title>2.1 Experimental studies</title>
                <p>

                    <bold>2.1.1 Liquid Chromatography-Mass Spectrometry (LC-MS) analysis</bold>
                </p>
                <p>The ethanol extract of Java cardamom seeds, which already extracted in our previous study, was analyzed using a UPLC BEH C18 column (1.7 &#x03bc;m, 2.1 &#x00d7; 50 mm) on an LC-MS system operating in positive ion mode. A sample volume of 5 &#x03bc;L was injected into the system for each run. The extract was prepared by dissolving 100 &#x03bc;L of the liquid extract in 900 &#x03bc;L of water, vortexed, and filtered through a 0.22 &#x03bc;m Millex filter before injection. The mobile phase consisted of solvent A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid). The separation was performed using gradient elution with the following profile: 95% A and 5% B at 0.4 minutes, gradually transitioning to 100% B over 15 minutes. The composition was held at 100% B for 0.1 minutes before returning to the initial condition of 95% A and 5% B at 15.1 minutes, which was maintained until 20 minutes for re-equilibration. The flow rate was set to 0.4 mL/min. Mass spectrometry was detected using electrospray ionization (ESI) in positive ion mode, with a mass range of 50&#x2013;1200 m/z. The capillary voltage was set to 0.5 kV, the cone voltage to 21 V, and the source temperature to 500&#x00b0;C (
                    <xref ref-type="bibr" rid="ref1">Abdallah et al., 2023</xref>; 
                    <xref ref-type="bibr" rid="ref10">Kaur et al., 2022</xref>).</p>
            </sec>
            <sec id="sec8">
                <title>2.2 In-Silico studies</title>
                <p>

                    <bold>2.2.1 Protein-protein interaction and protein network construction</bold>
                </p>
                <p>Protein-protein interaction (PPI) networks were constructed by integrating overlapping protein targets associated with breast cancer, utilizing multiple databases for comprehensive analysis. The process involves querying GeneCards and the Chemical Toxicogenomic Database using the search term &#x201c;breast cancer&#x201d; while incorporating predicted protein targets of cardamom compounds obtained from SwissTarget Prediction. The intersection of these protein sets is then input into the STRING database, specifically focusing on Homo sapiens with a medium confidence threshold (score &gt; 0.4). The resulting protein network is subsequently imported into Cytoscape, a network visualization software, for in-depth analysis and more representative visualization of the protein interactions (
                    <xref ref-type="bibr" rid="ref7">Hozhabri et al., 2022</xref>). This approach enables researchers to elucidate complex relationships between proteins involved in breast cancer and potential therapeutic targets, providing valuable insights into the molecular mechanisms underlying the disease. By leveraging multiple databases and sophisticated visualization tools, scientists can identify key nodes and clusters within the PPI network, potentially uncovering novel therapeutic targets or biomarkers for breast cancer.</p>
                <p>

                    <bold>2.2.2 Protein and ligand preparation</bold>
                </p>
                <p>Four selected proteins from the PPI network result were obtained from the PDB website (
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>; accessed November 14
                    <sup>th</sup>, 2024) (
                    <xref ref-type="table" rid="T1">
Table 1</xref>). The Biovia Discovery Studio v.2021 application was used to separate the control ligand from the three-dimensional crystal structure of the target protein. The two-dimensional structure of A. cardamomum&#x2019;s bioactive compounds was retrieved from the PubChem website in SDF format (
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>; accessed November 14
                    <sup>th</sup>, 2024). The MOE v2022.02 application was then used to conserve, neutralize, and refine all ligands and proteins to an RMS gradient of 0.001 kcal/mol/&#x00c5;2 (
                    <xref ref-type="bibr" rid="ref30">Yenny et al., 2024</xref>).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                    <label>
Table 1. </label>
                    <caption>
                        <title>Structural information of protein targets used in molecular docking analysis.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Protein</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">PDB ID</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Control ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Active site amino acid residue</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Casp3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5IBC</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">ACE-ASP-GLU-VAL-ASK</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">TRP206 ARG207 ASN208 ASP211 GLY212 TRP214 GLN217 PHE247 GLU248 SER249 PHE250</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">SRC</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2H8H</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Quinazoline</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">LEU273 GLY274 GLN275 GLY276 CYS277 PHE278 GLY279 GLU280 VAL281 ALA293 ILE294 LYS295 LEU297 MET314 VAL323 LEU325 ILE336 THR338 GLU339 TYR340 MET341 GLY344 SER345 LEU347 ASP348 ASP386 ARG388 ALA390 ASN391 LEU393 ALA403 ASP404 PHE405 LEU407 ALA408 ILE411 TYR416 LYS423 PRO425</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">TNF-&#x03b1;</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2AZ5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6,7-dimethyl-3-[(methyl {2-[methyl ({1-[3-(trifluoromethyl) phenyl]-1h-indol-3-yl} methyl) amino] ethyl} amino) methyl]-4h-chrome-4-one</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1:(HIS73 LYS98 SER99 PRO100 CYS101 GLU116 TYR119)2:(GLY68 CYS69 PRO70 ALA96 LYS98 PRO100 CYS101 GLN102 ARG103 LYS112 PRO113 TRP114 TYR115 GLU116 PRO117 ILE118 TYR119)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">EGFR</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1M17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Erlotinib</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">PHE699 VAL702 LYS721 LEU723 LYS730 ALA731 GLU734 ILE735 ASP737 GLU738 TYR740 VAL741 ARG812 ASP813 ARG817 ASN818 ASP831 PHE832 GLY833 LEU834 ALA835 LYS836 LEU837 TYR845 GLU848 LYS851 PRO853</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>2.2.3 Pharmacokinetic and pharmacodynamic analysis of 
                        <italic toggle="yes">A.cardamom</italic>um compounds</bold>
                </p>
                <p>Assessing a compound&#x2019;s absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics requires multiple computational methods. First, the canonical SMILES notation of the compound was obtained from the PubChem Database. The canonical SMILES notation of the compounds was then inserted into the SwissADME server (
                    <ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/index.php">http://www.swissadme.ch/index.php</ext-link>; accessed November 15
                    <sup>th</sup>, 2024) to determine the ADME (absorption, distribution, metabolism, and excretion) properties. Furthermore, the toxicity predictions of all the compounds were conducted using the ProTox-II server (
                    <ext-link ext-link-type="uri" xlink:href="http://tox-new.charite.de/protox_II">http://tox-new.charite.de/protox_II</ext-link>; accessed November 15
                    <sup>th</sup>, 2024) in compliance with the toxicity criteria set by the Organisation for Economic Cooperation and Development (OECD). The drug-likeness of the compound was assessed using Lipinski&#x2019;s rule of five criteria. The compounds were evaluated for their adherence to Lipinski&#x2019;s principles by submitting their canonical SMILE molecular structures to the Molinspiration Cheminformatics service (
                    <ext-link ext-link-type="uri" xlink:href="https://www.molinspiration.com/cgi/properties">https://www.molinspiration.com/cgi/properties</ext-link>; accessed November 15
                    <sup>th</sup>, 2024).</p>
                <p>

                    <bold>2.2.4 Molecular docking studies</bold>
                </p>
                <p>The MOE v2022.02 application was used to perform the molecular docking. MOE&#x2019;s Site Finder tool automatically finds the amino acid sequences of the target protein&#x2019;s active site (
                    <xref ref-type="table" rid="T1">
Table 1</xref>). The results of the molecular docking include 2D/3D visualization, Root Mean Square Deviation (RMSD) (&#x00c5;), and binding affinity (kcal/mol). Compounds are regarded as potent target protein inhibitors if their RMSD value is less than 2&#x00c5; and their binding affinity is much lower (more negative value) than the control ligand (
                    <xref ref-type="bibr" rid="ref30">Yenny et al., 2024</xref>). Additionally, the type and similarity of interaction between the chosen compound and the control ligand in the target protein&#x2019;s active site were used to visualize and ensure that the compound could act as a specific inhibitor of the target protein (
                    <xref ref-type="bibr" rid="ref22">Rita et al., 2025</xref>).</p>
                <p>

                    <bold>2.2.5 Molecular dynamic simulation</bold>
                </p>
                <p>The ligand with the lowest binding affinity was further analyzed through molecular dynamics simulation using Yet Another Scientific Artificial Reality Application (YASARA) software (
                    <xref ref-type="bibr" rid="ref13">Krieger &amp; Vriend, 2015</xref>). The simulation parameters were set at 25&#x00b0;C temperature, pH 7.4, and 0.9% salt concentration for a duration of 50 nanoseconds. This designated timeframe significantly exceeds the minimum duration required to assess protein-ligand complex stability, which is typically 20 nanoseconds (
                    <xref ref-type="bibr" rid="ref25">Wargasetia et al., 2021</xref>). The simulation was executed using the md_run macro program, and the results were analyzed using the md_analyze function.</p>
            </sec>
        </sec>
        <sec id="sec9" sec-type="results">
            <title>3. Results</title>
            <sec id="sec10">
                <title>3.1 Experimental studies</title>
                <p>

                    <bold>3.1.1 Liquid Chromatography-Mass Spectrometry (LC-MS) analysis</bold>
                </p>
                <p>The LC-MS analysis of 
                    <italic toggle="yes">Amomum cardamomum</italic> seed extract identified 22 unique compounds (
                    <xref ref-type="fig" rid="f1">
Figure 1</xref>, 
                    <xref ref-type="table" rid="T2">
Table 2</xref>). These compounds exhibit diverse molecular weights, retention times, and polarities, reflecting the chemical complexity of the extract. The retention times ranged from 0.52 to 17.09 minutes, and molecular weights varied between 113.115 Da (ethyl cyanoacetate) and 369.161 Da (1,2-diphenyl-3-(phenylmethyl)-1H-indene), highlighting the presence of both small and larger molecules.</p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>
Figure 1. </label>
                    <caption>
                        <title>Chromatogram (TIC) of 
                            <italic toggle="yes">A. cardamomum</italic> seed extract analyzed by LC-MS.</title>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_figure1.gif"/>
                </fig>
                <table-wrap id="T2" orientation="portrait" position="float">
                    <label>
Table 2. </label>
                    <caption>
                        <title>List of 
                            <italic toggle="yes">A. cardamomum</italic> compounds detected by LC-MS analysis.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">No</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Name</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RT</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Parent ion 
(M/Z)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Molecular formula [M-H]
                                    <sup>+</sup>
                                </th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Mass molecule 
(Da)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RT</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">7-(1,1-Dimethylethyl) 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.52</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">268.1297</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12H17N3O4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">267.281</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr5" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical1.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2,4,6-trimethylmelamine</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.994</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">169.1202</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6H12N6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">168.200</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr6" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical2.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1-Butyl-1H-imidazol 1-Butylimidazole</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.281</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">123.0949</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7H12N2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">124.184</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr7" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical3.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3-(5-Amino-3-methyl-pyrazole-1-yl)-propionitrile</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.702</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">151.1024</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7H10N4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150.181</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr8" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical4.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2-[Bis(2-hydroxyethyl)amino]propane-1,3-diol</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.803</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">180.1216</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7H17NO4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">179.214</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr9" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical5.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1,2-diphenyl-3-(phenylmethyl)-1H-indene
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.955</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">369.1614</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C28H21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">357.466</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr10" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical6.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Genipin</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.073</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">227.0964</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11H14O5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">226.226</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr11" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical7.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4H,6H-Furo[3,4-c][1,2,5]oxadiazol-4-one</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.343</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">127.0147</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4H2N2O3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">126.070</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr12" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical8.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4,6-Dimethyl-5-morpholin-4-ylpyrimidin-2-amine</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.596</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">209.1409</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10H16N4O</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">208.260</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr13" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical9.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">diglyme</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.916</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">135.1071</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6H14O3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">134.174</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr14" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical10.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">(R)-(+)-Pulegone</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.270</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">153.1255</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10H16O</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">152.233</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr15" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical11.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">trans-decalin
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.472</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">139.1534</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10H18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">138.250</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr16" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical12.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Seratrodast</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.624</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">355.1887</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22H26O4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">354.439</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr17" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical13.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">tert-butyl 2,4-dideoxy-3,5-O-(1-methyl ethylidene)-D-erythro-hexonate
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.826</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">261.1739</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13H24O5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">260.327</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr18" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical14.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2-Ethyl-N,N-bis(2-ethylhexyl) hexylamine</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4.012</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">340.3940</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C23H49N</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">339.642</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr19" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical15.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C16</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">N-Boc-piperidine-3-methanol</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4.315</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">216.1587</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11H21NO3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">215.289</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr20" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical16.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6,10-Dimethyl-1,3,5,7,9,11,12-tridecaneheptol</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4.871</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">325.2201</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15H32O7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">324.410</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr21" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical17.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Dihydroxymalonic acid</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5.697</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">137.0670</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3H4O6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">136.060</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr22" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical18.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Perillic alcohol</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6.254</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">153.0623</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10H16O</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">152.233</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr23" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical19.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">N-[(1-Ethyl-3-methyl-1H-pyrazole-4-yl)methyl]-N-[(1'-methyl-1,4'-bipiperidin-4-yl)methyl]ethanamine</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6.860</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">362.3331</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C21H39N5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">361.568</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr24" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical20.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Secoverine</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">7.838</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">346.2740</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22H35NO2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">345.519</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr25" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical21.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Ethyl cyanoacetate</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">17.092</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">114.0541</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5H7NO2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">113.115</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr26" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical22.gif"/>
</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec11">
                <title>3.2. In-silico studies</title>
                <p>

                    <bold>3.2.1 Protein-protein interaction network analysis</bold>
                </p>
                <p>The analysis of 22 compounds from cardamom extract revealed 512 potential targets based on Swiss target prediction. These results were compared with breast cancer-related genes from GeneCards (18,182 genes) and CTD (38,877 genes). A Venn diagram showed (
                    <xref ref-type="fig" rid="f2">
Figure 2</xref>.) 450 genes at the intersection of breast cancer and bioactive compounds from 
                    <italic toggle="yes">A. cardamomum</italic>, representing the overlap between cardamom-specific targets and breast cancer-related genes.</p>
                <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                    <label>
Figure 2. </label>
                    <caption>
                        <title>Veen Diagram of active compounds targets of A. cardamomum and breast cancer targets.</title>
                    </caption>
                    <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_figure2.gif"/>
                </fig>
                <p>To investigate the hub genes within key modules, a protein-protein interaction (PPI) network analysis was conducted using STRING with a confidence score &#x2265;0.4 for the biological species &#x201c;Homo sapiens&#x201d; (
                    <xref ref-type="fig" rid="f3">
Figure 3</xref>). This analysis revealed the synergistic and multi-targeted effects of A. compacta, contributing to its potential anticancer properties. As shown in 
                    <xref ref-type="fig" rid="f2">
Figure 2</xref>, topology analysis using Cytoscape was performed to calculate the centrality of each protein. The study identified CAS3, EGFR, SRC, and TNF-18 as key targets with the highest degree of connectivity, indicating their essential roles in the mechanisms of breast cancer (
                    <xref ref-type="fig" rid="f3">
Figure 3</xref>). These findings are supported by previous research highlighting the importance of these proteins in breast cancer progression and treatment resistance (
                    <xref ref-type="bibr" rid="ref7">Hozhabri et al., 2022</xref>).</p>
                <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                    <label>
Figure 3. </label>
                    <caption>
                        <title>Protein interaction network of A. cardamomum as a target of breast cancer treatment.</title>
                    </caption>
                    <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_figure3.gif"/>
                </fig>
                <p>The high centrality of these proteins in the PPI network suggests their critical roles in the complex interplay of molecular pathways involved in breast cancer. Their identification as key targets provide valuable insights into potential therapeutic strategies. Consequently, these proteins were selected as ideal candidates for further analysis through molecular docking and molecular dynamics simulations, which can offer a deeper understanding of their interactions with potential anticancer compounds and guide the development of more effective treatments for breast cancer (
                    <xref ref-type="bibr" rid="ref9">Kanhaiya et al., 2017</xref>).</p>
                <p>

                    <bold>3.2.2 Pharmacokinetic and pharmacodynamic analysis of 
                        <italic toggle="yes">A. cardamomum</italic> compound</bold>
                </p>
                <p>The pharmacokinetic and pharmacodynamic analysis of the 22 compounds identified in 
                    <italic toggle="yes">A. cardamomum</italic> seed extract revealed several key findings regarding their drug-likeness and potential therapeutic application (
                    <xref ref-type="table" rid="T3">
Table 3</xref>).</p>
                <table-wrap id="T3" orientation="portrait" position="float">
                    <label>
Table 3. </label>
                    <caption>
                        <title>Absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis result.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Compound</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">GI absorption</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Human oral bioavailability</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">BBB permeant</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">CYP2D6 substrate</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">CYP2D6 inhibitor</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">OCT2 Substrate</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Log S (ESOL)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">97.435 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-1.95 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">94.257 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-1.64 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">95.289 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-1.58 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">96.632 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.92 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">56.29 (Low)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.03 (Highly)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.94 (Poorly)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">59.431 (Low)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.56 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.57 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">98.73 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.74 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.74 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.05 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">96.77 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-2.72 (Soluble)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">94.707 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-3.61 (Soluble)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">93.316 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.85 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.43 (Moderately)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">94.923 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-1.77 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">87.773 (Low)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.68 (Poorly)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C16</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">90.877 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-1.65 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.32 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0 (Low)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.56 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.60 (Very)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">94.656 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.65 (Soluble)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">93.554 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-3.34 (Soluble)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">94.249 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Yes</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.70 (Moderately)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100 (High)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.55 (Good)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">No</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.58 (Very)</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.2.1 Absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis</bold>
                </p>
                <p>The pharmacokinetic evaluation (
                    <xref ref-type="table" rid="T3">
Table 3</xref>) revealed that most compounds from 
                    <italic toggle="yes">A. cardamomum</italic> seeds were predicted to have good gastrointestinal absorption, suggesting favorable uptake following oral administration. Only a few compounds, including C5, C7, C15, and C18, showed low absorption potential, indicating possible limitations in bioavailability. Consistent with these findings, nearly all compounds exhibited adequate oral bioavailability, reinforcing their potential for systemic circulation. Interestingly, several molecules, such as C1, C3, C11-C14, C16, C19-C21, were also predicted to penetrate the blood&#x2013;brain barrier, raising the possibility of central nervous system activity.</p>
                <p>In terms of metabolism, the majority of compounds were not identified as substrates or inhibitors of cytochrome P450 2D6 (CYP2D6), which reduces the likelihood of extensive enzyme-mediated clearance or drug&#x2013;drug interactions. Notably, C15 was predicted to act as a substrate, while C21 displayed inhibitory potential, highlighting that these particular molecules may influence or be influenced by drugs processed through CYP2D6.</p>
                <p>Excretion analysis indicated that almost all compounds were unlikely to interfere with renal elimination pathways. Only C15 demonstrated potential inhibitory activity toward the organic cation transporter OCT2, suggesting that most 
                    <italic toggle="yes">A. cardamomum</italic> constituents are unlikely to alter the renal clearance of co-administered drugs.</p>
                <p>Regarding solubility, the majority of compounds showed adequate water solubility, ranging from moderate to very soluble, which is advantageous for formulation and bioavailability. However, two compounds, C6 and C15, were categorized as poorly soluble, which could limit their practical application unless addressed by formulation strategies. Together, these findings suggest that the chemical profile of 
                    <italic toggle="yes">A. cardamomum</italic> seeds is largely consistent with drug-likeness criteria, although specific molecules may require optimization to overcome solubility or metabolic limitations.</p>
                <p>

                    <bold>3.2.2.2 Lipinski&#x2019;s rules of five</bold>
                </p>
                <p>Lipinski&#x2019;s rule of five indicates that 20 of the 22 evaluated compounds meet the criteria for drug-likeness compounds (
                    <xref ref-type="table" rid="T4">Table. 4</xref>). However, two compounds, C15 and C18, do not fully adhere to these criteria. C15 exhibits noncompliance due to the consensus log P value &gt;5 (6.964573) and molar refractivity &gt;130 (130.880981), which indicates potential challenges related to excessive lipophilicity and molecular size. LogP value indicates the level of lipophilicity, where high lipophilicity can result in quickly metabolized compounds, low solubility, and poorly absorbed (
                    <xref ref-type="bibr" rid="ref23">Rutkowska et al., 2013</xref>). Molar refractivity values within the range of 40-130 suggest that a substance is likely to have good intestinal absorption and oral bioavailability (
                    <xref ref-type="bibr" rid="ref28">Ya&#x2019;u Ibrahim et al., 2020</xref>). Conversely, C18 fails to meet the criteria because of its H-bond receptor count &gt;5 (6) and molar refractivity &lt;40 (17.236599), indicating potential issues with polarity and molecular size. The H-bond acceptor and H-bond donor present in the structure of a therapeutic agent play a vital role in membrane transport, drug-protein interactions, distribution, and aqueous solubility (
                    <xref ref-type="bibr" rid="ref11">Kenny, 2022</xref>). This evaluation provides valuable insights into the drug-like potential of the compounds from 
                    <italic toggle="yes">A. cardamomum.</italic>
                </p>
                <table-wrap id="T4" orientation="portrait" position="float">
                    <label>
Table 4. </label>
                    <caption>
                        <title>Lipinski&#x2019;s rules of five results of 
                            <italic toggle="yes">A.cardamomum</italic> compounds.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Compound</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Molecular weight (D) (g/mol)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Consensus log P</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">H-bond acceptor</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
H-bond donor</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Molar refractory</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Violation of Lipinski&#x2019;s rules</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>Standard</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>&lt;500</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>&#x2264; 5</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>&lt;5</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>&#x2264;10</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>40-130</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>&#x2264;1</bold>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">267</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.397590</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">64.743385</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">168</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.109530</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">42.125099</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">124</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.178840</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">37.558395</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.142820</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">39.077797</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">179</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.843730</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">47.034191</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">357</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5.262740</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">105.343987</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">226</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.603700</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">54.122093</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">126</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.663430</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">17.109299</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">208</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.361710</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">54.749691</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">134</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.803360</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35.653496</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">152</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.525599</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50.743492</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">138</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.837899</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">52.445992</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">312</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.053101</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">77.145782</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">260</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.034269</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">72.196793</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">339</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6.964573</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130.880981</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C16</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">215</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.270190</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">63.245789</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">324</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.838249</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">89.061790</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">136</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-0.715910</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">17.236599</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">152</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.232710</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50.070793</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">361</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3.902099</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">119.441383</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">345</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5.108690</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">112.781982</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">113</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.992430</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">26.986998</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.2.3 Toxicity prediction</bold>
                </p>
                <p>Based on the results of the toxicity analysis (
                    <xref ref-type="table" rid="T5">
Table 5</xref>), three compounds, namely C6, C7, and C14, were found to be in the toxic level (class I-III). Overall, one compound (C14) is classified as class two toxicity (fatal by ingestion (5 &lt; LD50 &#x2264; 50)), two compounds (C6 and C7) are classified as class III toxicity (toxic by ingestion (50 &lt; LD50 &#x2264; 300)), twelve compounds (C1, C2, C4, C5, C8, C9, C11, C13, C15, C16, C20, and C21) are classified as class IV toxicity (harmful if swallowed (300 &lt; LD50 &#x2264; 2000)), six compounds (C3, C10, C17, C18, C19, and C22) are classified as class V toxicity (may be harmful if swallowed (2000 &lt; LD50 &#x2264; 5000)), and one compound (C12) are classified as class VI toxicity (non-toxic (LD50 &gt; 5000)).</p>
                <table-wrap id="T5" orientation="portrait" position="float">
                    <label>
Table 5. </label>
                    <caption>
                        <title>Toxicity level and organ target toxicity prediction of 
                            <italic toggle="yes">A.cardamomum</italic> compounds.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="2" valign="top">Compound</th>
                                <th align="left" colspan="1" rowspan="2" valign="top">Predicted LD
                                    <sub>50</sub>
                                </th>
                                <th align="left" colspan="1" rowspan="2" valign="top">Predicted toxicity class</th>
                                <th align="left" colspan="1" rowspan="2" valign="top">
Average similarity</th>
                                <th align="left" colspan="5" rowspan="1" valign="top">Organ toxicity</th>
                            </tr>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Hepatotoxicity</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Carcinogenicity</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Immunotoxicity</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Mutagenicity</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">
Cytotoxicity</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">500 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">46.86%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">350 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3500 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">68.6%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1300 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">46.57%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3900 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">82.22%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">175 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Three (toxic)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">68.93%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">237 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Three (toxic)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1484 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">44.01%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">800 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">42.2%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4970 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">470 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">15380 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Six (non-toxic)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1520 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">44 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Two (fatal)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">80.22%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1400 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C16</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1000 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">64.91%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3000 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2450 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">84.86%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2100 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">500 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">51.4%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">369 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Four (harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4960 mg/kg</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Five (may be harmful)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Active</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Inactive</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <table-wrap id="T6" orientation="portrait" position="float">
                    <label>
Table 6. </label>
                    <caption>
                        <title>Molecular docking results of SRC, TNF-&#x03b1;, Casp3, and EGFR protein.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="2" valign="top">Compound</th>
                                <th align="left" colspan="2" rowspan="1" valign="top">SRC</th>
                                <th align="left" colspan="2" rowspan="1" valign="top">TNF-&#x03b1;</th>
                                <th align="left" colspan="2" rowspan="1" valign="top">Casp3</th>
                                <th align="left" colspan="2" rowspan="1" valign="top">EGFR</th>
                            </tr>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">BA</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RMSD</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">BA</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RMSD</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">BA</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RMSD</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">BA</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">RMSD</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Control</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.89</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.56</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.24</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.53</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.64</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.24</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.03</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.46</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.83</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.41</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.96</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.05</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.62</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.86</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.96</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.06</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.23</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.72</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.32</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.72</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.74</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.26</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.77</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.53</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.31</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.82</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.04</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.96</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.71</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.99</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.99</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.77</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.70</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.85</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.03</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.74</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.74</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.48</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.31</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.35</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.48</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.26</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.70</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6.32</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.31</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.67</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.02</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.61</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.37</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.40</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.45</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.05</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.46</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.27</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.29</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.21</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.72</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.33</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.26</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.83</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-3.87</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.64</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.51</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.24</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.38</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.68</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.76</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.97</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.91</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.70</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.33</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.37</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.97</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.90</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.30</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.34</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.87</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.75</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.68</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.37</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.33</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.27</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.87</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.45</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.74</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.64</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.89</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.27</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.78</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.57</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.90</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.90</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.23</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.90</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.09</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.77</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.67</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.42</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.32</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.66</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.83</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.91</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.72</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.57</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.02</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.85</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.03</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.17</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C16</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.94</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.55</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.64</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.91</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.55</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.26</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.41</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C17</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.84</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.82</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.91</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.41</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.70</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.51</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.58</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-3.65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.31</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.83</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-3.98</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.15</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C19</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.55</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.73</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.99</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.55</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.48</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.23</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.58</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.71</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.88</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.29</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.42</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.43</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.90</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C21</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-7.70</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.62</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.59</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.34</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.91</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-6.38</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.90</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C22</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-5.15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.93</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.09</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.05</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-4.52</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.76</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>Based on the analysis of organ toxicity, only 1 out of 22 compounds (C2) was reported to be active in the hepatotoxicity category. In the next category, 7 compounds (C4, C5, C6, C8, C10, C12, and C22) were reported as active carcinogenicity. Two out of 22 compounds (C4 and C8) were reportedly active in the mutagenicity. All evaluated compounds did not exhibit immunotoxicity or cytotoxicity. This is a positive sign that these compounds may not always risk genetic or cell damage, even if they are considered detrimental or possibly hazardous based on LD50 values [3]. Therefore, even if the chemicals from 
                    <italic toggle="yes">A. cardamomum</italic> have a variety of toxicity profiles, any prospective medicinal or pharmacological application must consider the unique risk factors associated with each component. Moreover, in vivo investigations are necessary to validate these in silico results and offer a more thorough comprehension of the safety and effectiveness of these substances.</p>
                <p>

                    <bold>3.2.3 Molecular docking</bold>
                </p>
                <p>The molecular docking analysis was conducted using the MOE application. To carry out a targeted molecular docking analysis, the grid box is accurately placed at the active site of each target protein. The grid box settings in the MOE application&#x2019;s Site Finder feature were automatically modified according to the amino acid residues corresponding to the natural ligand of each protein. Molecular docking results include binding affinity (measured in kcal/mol), RMSD (&#x00c5;), and visualization in two and three dimensions. A peptide with an RMSD below 2.5 &#x00c5; and a significantly higher binding affinity (more negative) than the control ligand may be regarded as a promising inhibitor of the target protein.</p>
                <p>

                    <bold>3.2.3.1 Molecular docking of SRC protein</bold>
                </p>
                <p>The molecular docking between SRC and 
                    <italic toggle="yes">Amomum cardamomum</italic> revealed that the compounds of 
                    <italic toggle="yes">Amomum cardamomum</italic> have RMSD values below 2&#x00c5;. Based on the binding affinity, C20 has the lowest binding affinity (-8.58 kcal/mol), stronger than the control ligand, with a binding energy of -7.89 kcal/mol (
                    <xref ref-type="table" rid="T6">
Table 6</xref>). C20 formed three interactions: one acidic hydrophilic (Asp404) and two greasy hydrophobic interactions (Ala390 and Phe405). Control ligand formed three interactions: one acidic hydrophilic (Asp404), one basic hydrophilic (Arg388), and one greasy hydrophobic interaction (Val281). These results showed that C20 interacts with Asp404, the same amino acid residue with which the control ligand interacts (
                    <xref ref-type="table" rid="T7">
Table 7</xref>). It can be concluded that C20 has the potential to be a new specific competitive inhibitor of SRC active site.</p>
                <table-wrap id="T7" orientation="portrait" position="float">
                    <label>
Table 7. </label>
                    <caption>
                        <title>Molecular docking result of SRC protein.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">2D Interaction</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">3D Interaction</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>Control</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr27" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical23.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr28" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical24.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>C20</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr29" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical25.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr30" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical26.gif"/>
</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.3.2 Molecular docking of TNF-&#x03b1; protein</bold>
                </p>
                <p>From the molecular docking result, C17 attaches to the TNF-&#x03b1; active site with minimal deviation, marked by RMSD &lt; 2&#x00c5; (1.41 &#x00c5;). C17 (-6.91 kcal/mol) has a binding affinity close to the control ligand&#x2019;s (-7.00 kcal/mol) (
                    <xref ref-type="table" rid="T6">
Table 6</xref>). C17 formed three polar hydrophilic interactions: TyrC119, TyrA119 and TyrA151. Meanwhile, the control ligand formed two polar hydrophilic interactions: TyrA119 and TyrA151. These showed that C17 and the control ligand interact with two similar amino acid residues of TNF-&#x03b1; (TyrA119 and TyrA151) (
                    <xref ref-type="table" rid="T8">
Table 8</xref>). So, C17 has the potential as a new specific competitive inhibitor of TNF-&#x03b1;.</p>
                <table-wrap id="T8" orientation="portrait" position="float">
                    <label>
Table 8. </label>
                    <caption>
                        <title>Molecular docking result of TNF-&#x03b1; protein.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">2D Interaction</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">3D Interaction</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>Control</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr31" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical27.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr32" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical28.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>C17</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr33" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical29.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr34" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical30.gif"/>
</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.3.3 Molecular docking of Casp3 protein</bold>
                </p>
                <p>All compounds of 
                    <italic toggle="yes">Amomum cardamomum</italic> have an RMSD value &lt; 2&#x00c5;. Based on the binding affinity, C17 has the highest binding affinity than the other compounds of 
                    <italic toggle="yes">A. (</italic>-6.70 kcal/mol) 
                    <italic toggle="yes">cardamomum</italic> and drug control (
                    <xref ref-type="table" rid="T6">
Table 6</xref>). The 2D interaction visualization revealed that C17 formed three interactions with the active site of casp3: one basic hydrophilic (Arg207), one polar hydrophilic (Asn208), and one greasy hydrophobic (Trp214) interaction. On the other hand, casp3 inhibitors formed one basic hydrophilic (Arg207) and two polar hydrophilic interactions (Thr62, Ser209) with the active site of casp3. This result showed that C17 and casp3 inhibitors formed one similar interaction with the active site of casp3 (Arg207) (
                    <xref ref-type="table" rid="T9">
Table 9</xref>). In conclusion, C17 has the potential as a new specific competitive inhibitor of the casp3 active site.</p>
                <table-wrap id="T9" orientation="portrait" position="float">
                    <label>
Table 9. </label>
                    <caption>
                        <title>Molecular docking results of casp3 protein.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">2D Interaction</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">3D Interaction</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>Control Drug</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr35" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical31.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr36" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical32.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>C17</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr37" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical33.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr38" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical34.gif"/>
</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.3.4 Molecular docking of EGFR protein</bold>
                </p>
                <p>All compounds of 
                    <italic toggle="yes">Amomum cardamomum</italic> have RMSD values below 2 &#x00c5;, except C15. Regarding binding affinity, C20 (-6.43 kcal/mol) has a binding affinity close to the control ligand (-6.47 kcal/mol) as the control ligand (
                    <xref ref-type="table" rid="T6">
Table 6</xref>). Although the binding affinity of C20 is not stronger than the control ligand, the difference in binding affinity is insignificant. The result of 2D interaction visualization showed that C21 formed two acidic hydrophilic interactions (Asp831 and Glu 738) with the active site of EGFR. Meanwhile, the control ligand formed one basic hydrophilic interaction (Lys721) and one greasy hydrophobic interaction (Phe699). Although C20 does not have identical amino acid residues as the control ligand, the 3D interaction visualization results show that C20 can occupy the binding site of the control ligand on the EGFR active site (
                    <xref ref-type="table" rid="T10">
Table 10</xref>).</p>
                <table-wrap id="T10" orientation="portrait" position="float">
                    <label>
Table 10. </label>
                    <caption>
                        <title>Molecular docking result of EGFR protein.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ligand</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">2D Interaction</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">3D Interaction</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>Control</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr39" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical35.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr40" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical36.gif"/>
</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <bold>C20</bold>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr41" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical37.gif"/>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <graphic id="gr42" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_Graphical38.gif"/>
</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>

                    <bold>3.2.4 Molecular dynamic simulation</bold>
                </p>
                <p>The graph illustrates that TNF&#x03b1;-C18 exhibits stable behavior, with RMSD values consistently around 1.5-2.0 Angstroms during the 50 nanoseconds simulation. SRC-C21 shows similar stability with RMSD fluctuating around 1.5-2.0 Angstroms, though with slightly more variation than TNF&#x03b1;-C18. EGFR-C21 demonstrates higher RMSD values (2.5-4.0 Angstroms) with significant fluctuations, particularly in the first 25 nanoseconds, before stabilizing around 2.5 Angstroms. CASP3-C18 shows the highest average RMSD values, maintaining levels between 3.0-3.5 Angstroms throughout the simulation with notable fluctuations. All molecular complexes reach relative stability after approximately 25 nanoseconds, though with different characteristic RMSD ranges (
                    <xref ref-type="fig" rid="f4">
Figure 4</xref>).</p>
                <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                    <label>
Figure 4. </label>
                    <caption>
                        <title>Root Mean Square Deviation (RMSD) trajectories of protein&#x2013;ligand complexes during 50 ns molecular dynamics simulation.</title>
                    </caption>
                    <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/185380/2ecce6bf-52ab-4c53-b973-1da0fbe26353_figure4.gif"/>
                </fig>
            </sec>
        </sec>
        <sec id="sec12" sec-type="discussion">
            <title>4. Discussion</title>
            <p>This study demonstrated the therapeutic potential of 
                <italic toggle="yes">A. cardamomum</italic> through a combination of LC-MS analysis, pharmacokinetic and pharmacodynamic prediction, network pharmacology, molecular docking, and molecular dynamic simulation. LC-MS analysis identified 22 unique compounds in the seed extract, showcasing a chemically diverse profile with various molecular weights and retention times. The protein-protein interaction (PPI) network studies revealed key protein targets for 
                <italic toggle="yes">A. cardamomum</italic> compounds, including SRC, EGFR, TNF-&#x03b1;, and Casp3, all of which play critical roles in breast cancer progression.</p>
            <p>SRC, a non-receptor tyrosine kinase and the first proto-oncogene identified in mammalian cells plays a crucial role in breast cancer (BC) by promoting tumor initiation, growth, metastasis, and drug resistance (
                <xref ref-type="bibr" rid="ref15">Luo et al., 2022</xref>). SRC is overexpressed or activated in various stages of BC, where it enhances signaling pathways that promote cell proliferation, survival, and motility, contributing to tumorigenesis. SRC activation leads to the phosphorylation of epidermal growth factor receptor (EGFR) (
                <xref ref-type="bibr" rid="ref5">Finn, 2008</xref>; 
                <xref ref-type="bibr" rid="ref19">Pelaz &amp; Tabernero, 2022</xref>; 
                <xref ref-type="bibr" rid="ref21">Raji et al., 2024</xref>; 
                <xref ref-type="bibr" rid="ref26">Wheeler et al., 2009</xref>). Additionally, SRC interacts with HER2, amplifying signaling through pathways like FAK and STAT3, which increase the metastatic potential and contribute to resistance against HER2-targeted therapies (
                <xref ref-type="bibr" rid="ref21">Raji et al., 2024</xref>). Inhibition of SRC has been shown to disrupt these pathways and reduce tumorigenesis, making SRC a critical target for therapeutic intervention in BC. One compound that can inhibit SRC activity is Quinazoline. Quinazoline exerts its effects by binding to the ATP-binding pocket of SRC, leading to the inhibition of its kinase activity. This interaction disrupts signaling pathways essential for tumor cell survival and growth, such as the PI3K-AKT and MAPK pathways (
                <xref ref-type="bibr" rid="ref4">Emami et al., 2022</xref>).</p>
            <p>Tumor necrosis factor (TNF-&#x03b1;) is a pro-inflammatory cytokine that plays a significant role in developing and progressing breast cancer. TNF-&#x03b1; is involved in carcinogenesis by activating several signaling pathways, including the TNF receptor 1 (TNFR1) pathway, which leads to the upregulation of oncoproteins such as HBXIP. This activation promotes cell proliferation, survival, and migration, contributing to tumorigenesis. Elevated TNF-&#x03b1; levels are often observed in breast cancer tissues, and its signaling is linked to increased metastasis and drug resistance, making TNF-&#x03b1; a critical factor in BC progression. Inhibition of TNF-&#x03b1; has been shown to reduce cancer cell proliferation, suppress tumor growth, and decrease metastatic potential. Consequently, TNF-&#x03b1; inhibitors are being explored as potential therapeutic agents for BC treatment. Targeting TNF-&#x03b1; makes it possible to disrupt its downstream signaling pathways, including the NF-&#x03ba;B and MAPK pathways, crucial for maintaining tumor cell survival and inducing inflammatory responses that support tumor growth (
                <xref ref-type="bibr" rid="ref2">Cai et al., 2017</xref>; 
                <xref ref-type="bibr" rid="ref18">Mercogliano et al., 2020</xref>). Given the importance of TNF-&#x03b1; in breast cancer progression, targeting its activity offers a promising strategy to mitigate carcinogenesis and enhance the efficacy of existing therapies.</p>
            <p>Caspase-3 (Casp3) plays a complex role in breast cancer, acting as a key apoptosis regulator, but its dysregulation can contribute to tumor progression and chemotherapy resistance (
                <xref ref-type="bibr" rid="ref20">Pu et al., 2017</xref>). High Casp3 expression is associated with poor prognosis, particularly in HER2-positive tumors and specific patient populations, while Casp3 deficiency reduces tumorigenesis in preclinical models (
                <xref ref-type="bibr" rid="ref20">Pu et al., 2017</xref>; 
                <xref ref-type="bibr" rid="ref32">Zhu et al., 2024</xref>). Casp3 activation is crucial for apoptosis, but its activity can be inhibited by factors such as the X-linked inhibitor of apoptosis protein (XIAP), which prevents its activation and subsequent cell death (
                <xref ref-type="bibr" rid="ref31">Yosefzon et al., 2018</xref>). These findings highlight Casp3&#x2019;s dual role in promoting tumorigenesis and resistance to treatment, suggesting it could be a target for therapeutic strategies in breast cancer.</p>
            <p>Epidermal growth factor receptor (EGFR) is a key player in breast cancer progression, as it regulates critical processes like cell proliferation, survival, migration, and differentiation. EGFR overexpression in breast cancer leads to the dysregulation of signaling pathways such as PI3K-AKT and MAPK, promoting tumorigenesis, metastasis, and resistance to apoptosis (
                <xref ref-type="bibr" rid="ref24">Sigismund et al., 2017</xref>). This is particularly evident in triple-negative breast cancer (TNBC), where EGFR overexpression is linked to poor prognosis. EGFR also interacts with other receptors, like HER2, amplifying tumor growth signals (
                <xref ref-type="bibr" rid="ref17">Masuda et al., 2012</xref>). Due to its central role, EGFR is potentially to be a target for therapeutic strategies</p>
        </sec>
        <sec id="sec13" sec-type="conclusion">
            <title>5. Conclusion</title>
            <p>The integration of molecular docking and dynamic simulation analyses provided robust evidence for the therapeutic potential of 
                <italic toggle="yes">A. cardamomum</italic> compounds, mainly C17 and C20, in targeting critical proteins involved in breast cancer. These compounds demonstrated strong binding affinities and maintained stable interactions with their targets during simulations, underscoring their potential as multi-targeted agents. However, further experimental validation is necessary to confirm these computational findings and evaluate the efficacy of these compounds in preclinical models. Pharmacokinetic and pharmacodynamic profiling revealed that most compounds exhibited favorable absorption, distribution, metabolism, and excretion (ADMET) properties, with 20 out of 22 compounds classified as highly absorbable and demonstrating good oral bioavailability. Notably, compounds such as C17 and C20 displayed the ability to cross the blood-brain barrier, suggesting potential utility in targeting breast cancer metastases to the central nervous system.</p>
        </sec>
        <sec id="sec14">
            <title>Ethics approval</title>
            <p>Ethics and consent were not required.</p>
        </sec>
    </body>
    <back>
        <sec id="sec17" sec-type="data-availability">
            <title>Data availability</title>
            <sec id="sec18">
                <title>Underlying data</title>
                <p>Zenodo: Exploration of 
                    <italic toggle="yes">Amomum cardamomum</italic> Seed-Derived Compounds: LC-MS Profiling, Network Pharmacology, and Computational Analyses for Innovative Multi-Targeted Breast Cancer Therapy. Doi: 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.17299396">https://doi.org/10.5281/zenodo.17299396</ext-link> (
                    <xref ref-type="bibr" rid="ref3">Cuandra, 2025</xref>).</p>
                <p>This project contains the following underlying data:
                    <list list-type="bullet">
                        <list-item>
                            <label>-</label>
                            <p>TNFA-KAPULAGA.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>CASP3-KAPULAGA.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>EGFR-KAPULAGA.xlsx</p>
                        </list-item>
                        <list-item>
                            <label>-</label>
                            <p>SRC-KAPULAGA.xlsx</p>
                        </list-item>
                    </list>
                </p>
                <p>Data are available under the terms of the 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link> (CC-BY 4.0).</p>
            </sec>
        </sec>
        <ack>
            <title>Acknowledgments</title>
            <p>The authors appreciate Dr. Prestasi&#x2019;s Bioinformatic Laboratory for their support of this manuscript.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Abdallah</surname>
                            <given-names>RH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Al-Saleem</surname>
                            <given-names>MSM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Abdel-Mageed</surname>
                            <given-names>WM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>LCMS/MS Phytochemical Profiling, Molecular, Pathological, and Immune-Histochemical Studies on the Anticancer Properties of Annona muricata.</article-title>
                    <source>

                        <italic toggle="yes">Molecules.</italic>
</source>
                    <year>2023</year>;<volume>28</volume>(<issue>15</issue>):<fpage>5744</fpage>.
                    <pub-id pub-id-type="pmid">37570713</pub-id>
                    <pub-id pub-id-type="doi">10.3390/MOLECULES28155744/S1</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10421100</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Cai</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cao</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Inflammatory factor TNF-&#x03b1; promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-&#x03ba;B (and/or p38)/p-STAT3/HBXIP/TNFR1.</article-title>
                    <source>

                        <italic toggle="yes">Oncotarget.</italic>
</source>
                    <year>2017</year>;<volume>8</volume>(<issue>35</issue>):<fpage>58338</fpage>&#x2013;<lpage>58352</lpage>.
                    <pub-id pub-id-type="pmid">28938560</pub-id>
                    <pub-id pub-id-type="doi">10.18632/ONCOTARGET.16873</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5601656</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <mixed-citation publication-type="other">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Cuandra</surname>
                            <given-names>K</given-names>
                        </name>
</person-group>:
                    <article-title>Exploration of Amomum cardamomum Seed-Derived Compounds: LC-MS Profiling, Network Pharmacology, and Computational Analyses for Innovative Multi-Targeted Breast Cancer Therapy.</article-title>
                    <year>2025</year>.
                    <pub-id pub-id-type="doi">10.5281/ZENODO.17299396</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Emami</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khabnadideh</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Faghih</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Synthesis, biological evaluation, and computational studies of some novel quinazoline derivatives as anticancer agents.</article-title>
                    <source>

                        <italic toggle="yes">BMC Chemistry.</italic>
</source>
                    <year>2022</year>;<volume>16</volume>(<issue>1</issue>):<fpage>100</fpage>.
                    <pub-id pub-id-type="pmid">36419100</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s13065-022-00893-z</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9682696</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Finn</surname>
                            <given-names>RS</given-names>
                        </name>
</person-group>:
                    <article-title>Targeting Src in breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Ann. Oncol.</italic>
</source>
                    <year>2008</year>;<volume>19</volume>(<issue>8</issue>):<fpage>1379</fpage>&#x2013;<lpage>1386</lpage>.
                    <pub-id pub-id-type="doi">10.1093/annonc/mdn291</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Francies</surname>
                            <given-names>FZ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hull</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khanyile</surname>
                            <given-names>R</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Cancer Res.</italic>
</source>
                    <year>2020</year>;<volume>10</volume>(<issue>5</issue>):<fpage>1568</fpage>&#x2013;<lpage>1591</lpage>.
                    <pub-id pub-id-type="pmid">32509398</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7269781/">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hozhabri</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dehkohneh</surname>
                            <given-names>RSG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Razavi</surname>
                            <given-names>SM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Comparative analysis of protein-protein interaction networks in metastatic breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">PLOS ONE.</italic>
</source>
                    <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>e0260584</fpage>.
                    <pub-id pub-id-type="pmid">35045088</pub-id>
                    <pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0260584</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8769308</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kanhaiya</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Czeizler</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gratie</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Controlling Directed Protein Interaction Networks in Cancer.</article-title>
                    <source>

                        <italic toggle="yes">Sci. Rep.</italic>
</source>
                    <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>10312</fpage>&#x2013;<lpage>10327</lpage>.
                    <pub-id pub-id-type="pmid">28871116</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41598-017-10491-y</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5583175</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kaur</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dhiman</surname>
                            <given-names>V</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bhadada</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>LC/MS guided identification of metabolites of different extracts of Cissus quadrangularis.</article-title>
                    <source>

                        <italic toggle="yes">Food Chemistry Advances.</italic>
</source>
                    <year>2022</year>;<volume>1</volume>:<fpage>100084</fpage>.
                    <pub-id pub-id-type="doi">10.1016/j.focha.2022.100084</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kenny</surname>
                            <given-names>PW</given-names>
                        </name>
</person-group>:
                    <article-title>Hydrogen-Bond Donors in Drug Design.</article-title>
                    <source>

                        <italic toggle="yes">J. Med. Chem.</italic>
</source>
                    <year>2022</year>;<volume>65</volume>(<issue>21</issue>):<fpage>14261</fpage>&#x2013;<lpage>14275</lpage>.
                    <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01147</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Khairani</surname>
                            <given-names>SP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cuandra</surname>
                            <given-names>KN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ramadhannisa</surname>
                            <given-names>ZD</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Unravelling the apoptosis induction potential of Amomum cardamomum seed: A combination in silico and in vitro approach.</article-title>
                    <source>

                        <italic toggle="yes">Journal of Herbmed Pharmacology.</italic>
</source>
                    <year>2024</year>;<volume>13</volume>(<issue>3</issue>):<fpage>427</fpage>&#x2013;<lpage>438</lpage>.
                    <pub-id pub-id-type="doi">10.34172/JHP.2024.49345</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Krieger</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Vriend</surname>
                            <given-names>G</given-names>
                        </name>
</person-group>:
                    <article-title>New ways to boost molecular dynamics simulations.</article-title>
                    <source>

                        <italic toggle="yes">J. Comput. Chem.</italic>
</source>
                    <year>2015</year>;<volume>36</volume>(<issue>13</issue>):<fpage>996</fpage>&#x2013;<lpage>1007</lpage>.
                    <pub-id pub-id-type="pmid">25824339</pub-id>
                    <pub-id pub-id-type="doi">10.1002/JCC.23899</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6680170</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tan</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Exploring treatment options in cancer: tumor treatment strategies.</article-title>
                    <source>

                        <italic toggle="yes">Signal Transduct. Target. Ther.</italic>
</source>
                    <year>2024</year>;<volume>9</volume>(<issue>1</issue>):<fpage>144</fpage>&#x2013;<lpage>175</lpage>.
                    <pub-id pub-id-type="pmid">39013849</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41392-024-01856-7</pub-id>
                    <pub-id pub-id-type="pmcid">PMC11252281</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Luo</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zou</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Breast Cancer Res.</italic>
</source>
                    <year>2022</year>;<volume>24</volume>(<issue>1</issue>):<fpage>99</fpage>.
                    <pub-id pub-id-type="pmid">36581908</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s13058-022-01596-y</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9798727</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Manson</surname>
                            <given-names>EN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Achel</surname>
                            <given-names>DG</given-names>
                        </name>
</person-group>:
                    <article-title>Fighting breast cancer in low-and-middle-income countries &#x2013; What must we do to get every woman screened on regular basis?</article-title>
                    <source>

                        <italic toggle="yes">Scientific African.</italic>
</source>
                    <year>2023</year>;<volume>21</volume>:<fpage>e01848</fpage>.
                    <pub-id pub-id-type="doi">10.1016/J.SCIAF.2023.E01848</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Masuda</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bartholomeusz</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Role of Epidermal Growth Factor Receptor in Breast Cancer.</article-title>
                    <source>

                        <italic toggle="yes">Breast Cancer Res. Treat.</italic>
</source>
                    <year>2012</year>;<volume>136</volume>(<issue>2</issue>):<fpage>331</fpage>&#x2013;<lpage>345</lpage>.
                    <pub-id pub-id-type="pmid">23073759</pub-id>
                    <pub-id pub-id-type="doi">10.1007/S10549-012-2289-9</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3832208</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Mercogliano</surname>
                            <given-names>MF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bruni</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Elizalde</surname>
                            <given-names>PV</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Tumor Necrosis Factor &#x03b1; Blockade: An Opportunity to Tackle Breast Cancer.</article-title>
                    <source>

                        <italic toggle="yes">Front. Oncol.</italic>
</source>
                    <year>2020</year>;<volume>10</volume>:<fpage>584</fpage>.
                    <pub-id pub-id-type="pmid">32391269</pub-id>
                    <pub-id pub-id-type="doi">10.3389/FONC.2020.00584</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7189060</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pelaz</surname>
                            <given-names>SG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tabernero</surname>
                            <given-names>A</given-names>
                        </name>
</person-group>:
                    <article-title>Src: coordinating metabolism in cancer.</article-title>
                    <source>

                        <italic toggle="yes">Oncogene.</italic>
</source>
                    <year>2022</year>;<volume>41</volume>(<issue>45</issue>):<fpage>4917</fpage>&#x2013;<lpage>4928</lpage>.
                    <pub-id pub-id-type="pmid">36217026</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41388-022-02487-4</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9630107</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pu</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Storr</surname>
                            <given-names>SJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival.</article-title>
                    <source>

                        <italic toggle="yes">Apoptosis.</italic>
</source>
                    <year>2017</year>;<volume>22</volume>(<issue>3</issue>):<fpage>357</fpage>&#x2013;<lpage>368</lpage>.
                    <pub-id pub-id-type="pmid">27798717</pub-id>
                    <pub-id pub-id-type="doi">10.1007/S10495-016-1323-5/TABLES/5</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5306438</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Raji</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tetteh</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Amin</surname>
                            <given-names>ARMR</given-names>
                        </name>
</person-group>:
                    <article-title>Role of c-Src in Carcinogenesis and Drug Resistance.</article-title>
                    <source>

                        <italic toggle="yes">Cancers.</italic>
</source>
                    <year>2024</year>;<volume>16</volume>(<issue>1</issue>).
                    <pub-id pub-id-type="pmid">38201459</pub-id>
                    <pub-id pub-id-type="doi">10.3390/cancers16010032</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10778207</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rita</surname>
                            <given-names>RS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cuandra</surname>
                            <given-names>KN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khairani</surname>
                            <given-names>SP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Bioinformatic investigation of Lytechinus variegatus coelomic fluid peptides as multiple oncogenic proteins inhibitors of colorectal cancer.</article-title>
                    <source>

                        <italic toggle="yes">Journal of Pharmacy and Pharmacognosy Research.</italic>
</source>
                    <year>2025</year>;<volume>13</volume>(<issue>1</issue>):<fpage>341</fpage>&#x2013;<lpage>355</lpage>.
                    <pub-id pub-id-type="doi">10.56499/JPPRES24.2085_13.1.341</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rutkowska</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pajak</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>J&#x00f3;&#x017a;wiak</surname>
                            <given-names>K</given-names>
                        </name>
</person-group>:
                    <article-title>Lipophilicity--methods of determination and its role in medicinal chemistry.</article-title>
                    <source>

                        <italic toggle="yes">Acta Pol. Pharm.</italic>
</source>
                    <year>2013</year>;<volume>70</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>18</lpage>.
                    <pub-id pub-id-type="pmid">23610954</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref24">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sigismund</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Avanzato</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lanzetti</surname>
                            <given-names>L</given-names>
                        </name>
</person-group>:
                    <article-title>Emerging functions of the EGFR in cancer.</article-title>
                    <source>

                        <italic toggle="yes">Mol. Oncol.</italic>
</source>
                    <year>2017</year>;<volume>12</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>20</lpage>.
                    <pub-id pub-id-type="pmid">29124875</pub-id>
                    <pub-id pub-id-type="doi">10.1002/1878-0261.12155</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5748484</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wargasetia</surname>
                            <given-names>TL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ratnawati</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Widodo</surname>
                            <given-names>N</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).</article-title>
                    <source>

                        <italic toggle="yes">Cancer Informat.</italic>
</source>
                    <year>2021</year>;<volume>20</volume>:<fpage>11769351211031864</fpage>.
                    <pub-id pub-id-type="pmid">34345161</pub-id>
                    <pub-id pub-id-type="doi">10.1177/11769351211031864</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8283226</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wheeler</surname>
                            <given-names>DL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iida</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dunn</surname>
                            <given-names>EF</given-names>
                        </name>
</person-group>:
                    <article-title>The Role of Src in Solid Tumors.</article-title>
                    <source>

                        <italic toggle="yes">Oncologist.</italic>
</source>
                    <year>2009</year>;<volume>14</volume>(<issue>7</issue>):<fpage>667</fpage>&#x2013;<lpage>678</lpage>.
                    <pub-id pub-id-type="pmid">19581523</pub-id>
                    <pub-id pub-id-type="doi">10.1634/theoncologist.2009-0009</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3303596</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref27">
                <mixed-citation publication-type="other">
                    <collab>World Health Organization</collab>:
                    <article-title>Cancer Today.</article-title>
                    <year>2024, February 8</year>.
                    <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&amp;group_populations=1&amp;populations=900&amp;types=0">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref28">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ya&#x2019;u Ibrahim</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Uzairu</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Shallangwa</surname>
                            <given-names>G</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Molecular docking studies, drug-likeness and in-silico ADMET prediction of some novel &#x03b2;-Amino alcohol grafted 1,4,5-trisubstituted 1,2,3-triazoles derivatives as elevators of p53 protein levels.</article-title>
                    <source>

                        <italic toggle="yes">Scientific African.</italic>
</source>
                    <year>2020</year>;<volume>10</volume>:<fpage>e00570</fpage>.
                    <pub-id pub-id-type="doi">10.1016/j.sciaf.2020.e00570</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref29">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ye</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dewanjee</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.</article-title>
                    <source>

                        <italic toggle="yes">Mol. Cancer.</italic>
</source>
                    <year>2023</year>;<volume>22</volume>(<issue>1</issue>):<fpage>105</fpage>&#x2013;<lpage>140</lpage>.
                    <pub-id pub-id-type="pmid">37415164</pub-id>
                    <pub-id pub-id-type="doi">10.1186/S12943-023-01805-Y</pub-id>
                    <pub-id pub-id-type="pmcid">PMC10324146</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref30">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yenny</surname>
                            <given-names>SW</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jamsari</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hazmi</surname>
                            <given-names>AA</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>In silico analysis of Arbacia lixula-derived peptides and plasmid construction for recombinant anti-aging therapies.</article-title>
                    <source>

                        <italic toggle="yes">Narra J.</italic>
</source>
                    <year>2024</year>;<volume>4</volume>(<issue>3</issue>):<fpage>e1283</fpage>&#x2013;<lpage>e1283</lpage>.
                    <pub-id pub-id-type="pmid">39816070</pub-id>
                    <pub-id pub-id-type="doi">10.52225/NARRA.V4I3.1283</pub-id>
                    <pub-id pub-id-type="pmcid">PMC11731804</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref31">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yosefzon</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Soteriou</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Feldman</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Caspase-3 Regulates YAP-Dependent Cell Proliferation and Organ Size.</article-title>
                    <source>

                        <italic toggle="yes">Mol. Cell.</italic>
</source>
                    <year>2018</year>;<volume>70</volume>(<issue>4</issue>):<fpage>573</fpage>&#x2013;<lpage>587.e4</lpage>.
                    <pub-id pub-id-type="pmid">29775577</pub-id>
                    <pub-id pub-id-type="doi">10.1016/J.MOLCEL.2018.04.019/ATTACHMENT/1FD9981F-EC5C-4141-8626-F0964EB31B82/MMC2.PDF</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref32">
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zhu</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fan</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>CY</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Caspase-3 promotes oncogene-induced malignant transformation via EndoG-dependent Src-STAT3 phosphorylation.</article-title>
                    <source>

                        <italic toggle="yes">Cell Death &amp; Disease.</italic>
</source>
                    <year>2024</year>;<volume>15</volume>(<issue>7</issue>):<fpage>410</fpage>&#x2013;<lpage>486</lpage>.
                    <pub-id pub-id-type="pmid">38977663</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41419-024-06884-3</pub-id>
                    <pub-id pub-id-type="pmcid">PMC11231138</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report473521">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.185380.r473521</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Javrushyan</surname>
                        <given-names>Hayarpi</given-names>
                    </name>
                    <xref ref-type="aff" rid="r473521a1">1</xref>
                    <role>Referee</role>
                </contrib>
                <aff id="r473521a1">
                    <label>1</label>Research Institute of Biology, Yerevan State University, Yerevan, Armenia</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>20</day>
                <month>4</month>
                <year>2026</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2026 Javrushyan H</copyright-statement>
                <copyright-year>2026</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport473521" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.168214.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This manuscript presents an integrated in silico investigation of 
                <italic>Amomum cardamomum</italic> seed-derived compounds as potential multi-target agents against breast cancer, combining LC&#x2013;MS profiling, network pharmacology, ADMET prediction, molecular docking, and molecular dynamics simulations. The topic is relevant and timely, and the overall approach&#x2014;linking phytochemical profiling with computational analyses&#x2014;is appropriate and of potential interest.</p>
            <p> However, in my view, the manuscript in its current form has several important methodological limitations and internal inconsistencies that significantly weaken the strength of the conclusions.</p>
            <p> One of the main concerns relates to the inconsistency between the compounds highlighted as leads and those subjected to molecular dynamics simulations. While C17 and C20 are presented throughout as the most promising candidates, the MD simulations were performed on different compounds (C18 and C21). The abstract and conclusions nevertheless state that the stability of C17 and C20 was confirmed by MD simulations, which is not supported by the data shown. This is not a minor issue and needs to be resolved either by performing simulations on the correct compounds or by revising the manuscript to ensure internal consistency.</p>
            <p> More generally, the manuscript tends to overinterpret in silico results. Statements describing compounds as &#x201c;specific inhibitors&#x201d; or &#x201c;therapeutic candidates&#x201d; go beyond what can be concluded from docking and MD simulations alone. These approaches provide useful predictions of potential interactions, but they do not demonstrate biological activity or efficacy. The conclusions should therefore be tempered, and the predictive nature of the findings should be clearly acknowledged.</p>
            <p> Another point that requires attention is the identification of compounds by LC&#x2013;MS. At present, the manuscript does not provide sufficient validation (e.g., MS/MS fragmentation data, reference standards, or clear database matching criteria). In addition, some of the reported compounds appear unusual for plant-derived metabolites, which raises the possibility of misannotation or contamination. Since all downstream analyses depend on the correctness of compound identification, this aspect needs to be clarified.</p>
            <p> The network pharmacology analysis would also benefit from more stringent filtering. The use of very large gene sets from databases such as GeneCards and CTD makes the overlap relatively non-specific and difficult to interpret biologically. Applying stricter criteria and including pathway enrichment analysis would strengthen this part of the study.</p>
            <p> From a methodological perspective, the docking procedure lacks validation details (e.g., redocking), and there is some inconsistency in the reported RMSD thresholds. Similarly, the molecular dynamics analysis relies mainly on RMSD, without additional parameters such as RMSF or interaction analysis, which limits the strength of the conclusions regarding complex stability.</p>
            <p> There are also a few inconsistencies in data interpretation, for example, in the discussion of ADMET results (including BBB permeability) and in the description of transporter-related properties. These should be carefully revised to ensure that all statements are directly supported by the presented data. Minor issues include typographical errors, inconsistent nomenclature, and figures that could be improved for clarity.</p>
            <p> Thus, while the study has potential and follows a commonly used computational workflow, the current version requires substantial revision to ensure methodological transparency, internal consistency, and appropriately supported conclusions.</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Partly</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Not applicable</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Partly</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Partly</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Partly</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Biochemistry, Cancer Biology</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report445457">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.185380.r445457</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Yu</surname>
                        <given-names>Jun Sang</given-names>
                    </name>
                    <xref ref-type="aff" rid="r445457a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-5720-5934</uri>
                </contrib>
                <aff id="r445457a1">
                    <label>1</label>Jeju National University, Jeju-si, Jeju-do, South Korea</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>28</day>
                <month>1</month>
                <year>2026</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2026 Yu JS</copyright-statement>
                <copyright-year>2026</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport445457" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.168214.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>I have reviewed the above manuscript. The study combines LC&#x2013;MS-based compound identification with network pharmacology, molecular docking, and molecular dynamics simulations to explore potential bioactive compounds. While the overall in silico workflow is familiar and generally acceptable for a descriptive study, several issues related to data consistency, methodological correctness, and result interpretation require clarification and correction. These concerns are largely addressable without additional experiments; therefore, I recommend 
                <bold>minor revision</bold>.</p>
            <p> </p>
            <p> 
                <bold>1) Table 2: duplicated compound index and incorrect ion notation</bold>
            </p>
            <p> In Table 2, compound 
                <bold>C22 appears twice</bold>, indicating an indexing or annotation error that should be corrected. In addition, the reported ion form 
                <bold>[M&#x2013;H]+ is not standard</bold>. In mass spectrometry, positive ion mode is conventionally expressed as 
                <bold>[M+H]+</bold>, whereas 
                <bold>[M&#x2013;H]&#x2212;</bold> corresponds to negative ion mode. Since the manuscript states that the analysis was performed in positive ion mode, the ion notation should be revised for correctness and clarity.</p>
            <p> </p>
            <p> 
                <bold>2)&#x00a0;Figure 3 lacks clear scientific meaning and interpretability</bold>
            </p>
            <p> It is difficult to understand what Figure 3 is intended to demonstrate. The presented network visualization does not convey quantitative or interpretable information, and no network metrics or analytical conclusions are directly supported by the figure. As currently shown, the figure appears largely illustrative rather than informative. The authors should clarify its purpose, improve its interpretability, or reconsider its inclusion.</p>
            <p> </p>
            <p> 
                <bold>3)&#x00a0;Questionable classification of several compounds as &#x201c;seed-derived&#x201d;</bold>
            </p>
            <p> The manuscript repeatedly refers to the identified compounds as 
                <italic>seed-derived</italic>. However, several compounds listed in Table 2 are difficult to reconcile with known plant secondary metabolites and may reflect contamination or database misannotation rather than genuine seed constituents. Without additional justification or validation, the use of the term 
                <italic>seed-derived compounds</italic> appears overstated and should be reconsidered or more carefully qualified.</p>
            <p> </p>
            <p> 
                <bold>4)&#x00a0;Misinterpretation of ADMET results: OCT2 substrate vs inhibitor</bold>
            </p>
            <p> In the ADMET analysis, Table 3 reports OCT2 
                <bold>substrate</bold> status, yet the manuscript text describes this as 
                <bold>inhibitory activity</bold> toward OCT2. These two terms have fundamentally different pharmacokinetic implications. The text should be corrected to accurately reflect the reported data.</p>
            <p> </p>
            <p> 
                <bold>5)&#x00a0;Inconsistency between BBB permeability results and conclusions</bold>
            </p>
            <p> The conclusions state that both 
                <bold>C17 and C20 are BBB-permeant</bold>, whereas Table 3 reports 
                <bold>C17 as BBB permeant = No</bold>. This represents a direct inconsistency between the tabulated results and the written conclusions. The authors should revise the conclusion or clarify the basis for this claim.</p>
            <p> </p>
            <p> 
                <bold>6)&#x00a0;Mismatch between highlighted lead compounds and MD simulations</bold>
            </p>
            <p> The manuscript emphasizes 
                <bold>C17 and C20</bold> as key compounds; however, the molecular dynamics simulations were performed on 
                <bold>C18 and C21</bold>. Furthermore, the abstract states that MD simulations confirmed the stability of C17 and C20, which is not supported by the presented MD results. This discrepancy between the abstract, methods, and results should be resolved to ensure internal consistency.</p>
            <p> </p>
            <p> Overall, the manuscript presents a conventional in silico screening workflow, but several internal inconsistencies, incorrect interpretations, and unclear presentations undermine the clarity and reliability of the conclusions. These issues appear correctable through careful revision of tables, figures, and text, and therefore a decision of 
                <italic>minor revision</italic> is appropriate.</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Partly</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Partly</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Partly</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Pharmacokinetics, ADME, Pharmaceutical analysis, Mass spectrometry, GNPS</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
</article>
